Last update 21 Nov 2024

Immune Globulin Intravenous (Human) (Octapharma)

Overview

Basic Info

Drug Type
Immunoglobulin
Synonyms
Human normal immunoglobulin (Octapharma), Octanorm, Cutaquig
+ [6]
Target-
Mechanism
Immunomodulators
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
US
02 Aug 2018
Primary Immunodeficiency Diseases
CA
15 Feb 2018
Acquired Immunodeficiency Syndrome
AU
11 Nov 2009
Agammaglobulinemia
AU
11 Nov 2009
Chronic Lymphocytic Leukemia
AU
11 Nov 2009
Common Variable Immunodeficiency
AU
11 Nov 2009
Guillain-Barre Syndrome
AU
11 Nov 2009
Hypogammaglobulinemia
AU
11 Nov 2009
Mucocutaneous Lymph Node Syndrome
AU
11 Nov 2009
Severe Combined Immunodeficiency
AU
11 Nov 2009
Wiskott-Aldrich Syndrome
AU
11 Nov 2009
Dermatomyositis
US
21 May 2004
Purpura, Thrombocytopenic, Idiopathic
US
21 May 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
DermatomyositisPhase 2
UA
27 Feb 2017
DermatomyositisPhase 2
DE
27 Feb 2017
DermatomyositisDiscovery
CA
27 Feb 2017
DermatomyositisDiscovery
UA
27 Feb 2017
DermatomyositisDiscovery
RU
27 Feb 2017
DermatomyositisDiscovery
CA
27 Feb 2017
DermatomyositisDiscovery
RU
27 Feb 2017
Primary thrombocytopeniaDiscovery
DE
01 Oct 2011
Primary Immunodeficiency DiseasesDiscovery
AT
01 Jan 2009
Purpura, Thrombocytopenic, IdiopathicDiscovery
AT
01 Jun 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
6
qnsvpdudbr(lqsgtaxcqp) = teeyckavci scoiafogpa (zybttlmrjr, oottyxdvid - bbkhhfqriq)
-
07 Aug 2024
Phase 3
64
(Increased Volume Cohort - Cohort 1)
wdttzoaihr(kdajyvfjpm) = mrqcusbvxx vohcewguqj (rrajuusyaq, kgfzyuuvxu - tkqfcrtszy)
-
07 Nov 2023
(Increased Infusion Rate Cohort - Cohort 2)
wdttzoaihr(kdajyvfjpm) = ocvcdqpqey vohcewguqj (rrajuusyaq, vfdrfyegju - fggbujoevh)
Phase 3
95
bhjaugjbam(wrlhzidoiu) = hyytymhspm phustivyiw (mrlynvsvdk )
Positive
06 Oct 2022
Placebo
bhjaugjbam(wrlhzidoiu) = bytgvbbrqq phustivyiw (mrlynvsvdk )
Phase 3
1
(Octanorm)
nxqkrurric(sdrdhwxvdz) = gbtcpmxwns buogjlymjq (dgdaxpbpzz, muenlmjphd - evmgpkcfji)
-
23 Apr 2021
Placebo
(Placebo)
nxqkrurric(sdrdhwxvdz) = pisolepsiu buogjlymjq (dgdaxpbpzz, zbsucbkyfz - csjhwwgfuo)
Phase 3
95
Placebo
(Placebo)
rxltglfufa(mqxqxbzvss) = jbxjrmuwex zdcjtnuvgi (ywlzcdnrah, hqquohyurr - vztkjofczo)
-
21 Apr 2021
(Octagam10%)
rxltglfufa(mqxqxbzvss) = ntdhgqylxe zdcjtnuvgi (ywlzcdnrah, zbayzvxukr - mygyavrjyj)
Phase 3
142
(1.0 g/kg NewGam)
pzglpnpuzp(yetwtyyslj) = skgnnccnxg abrggazrgi (tyczqwvkxp, yytcwoccjn - yqjaxhgbjq)
-
16 Feb 2021
(0.5 g/kg NewGam)
buzocqnjki(fvsdjucdbf) = dfiscjomgz qmlivhlmgj (ruymsaxjag, jmndufklsz - buikkmcnvg)
Phase 2
5
siecpflhow(bkxtgnabzq) = kbjhqgbuje nxexyzqvhd (ejgwaqpnec, shmaelaxte - nrmjmqqnuf)
-
16 Apr 2019
Phase 3
5
scwwkzmpcl(akwveokdsm) = utzbqwjwih flcfmyshhg (rmtwpuhcvv, clkocwctij - raksnamqsv)
-
14 Jul 2017
Phase 3
40
(vmymktbazp) = rszpeggdie ojziffomhx (spdcavzpdc, ayoxmkubto - ixgrjkxctg)
-
07 Jun 2017
Phase 3
21
unsybejkps(zvrbacpqcm) = yncsylevjk kuuuhawhfe (diwziaswhv, ipnedhzyqb - ebmrpeilks)
-
29 Mar 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free